Mark Witmer
About Mark Witmer
Mark Witmer is the Scientific Senior Director at Bristol-Myers Squibb, with extensive experience in protein science and drug discovery.
Current Position at Bristol-Myers Squibb
Mark Witmer currently holds the position of Scientific Senior Director at Bristol-Myers Squibb. In this role, he operates on-site and is instrumental in leading scientific initiatives and collaborations. His responsibilities include overseeing various projects and ensuring the delivery of qualified protein reagents for commercial and academic collaborations.
Career History at Bristol-Myers Squibb
Mark Witmer has a long-standing career at Bristol-Myers Squibb, with notable positions including Director from 2019 to 2020, and Senior Principal Scientist from 2014 to 2019. He has amassed extensive experience within the company, particularly in Princeton, New Jersey. Throughout his tenure, he has demonstrated expertise in drug discovery and the management of scientific teams.
Educational Background
Mark Witmer holds a Ph.D. in Organic Chemistry from Cornell University, obtained from 1985 to 1990. He also completed a Bachelor of Science in Chemistry at Lebanon Valley College from 1981 to 1985. Furthering his education, he conducted post-doctoral work in Protein Biochemistry at Penn State University from 1990 to 1992. His educational background has laid a strong foundation for his contributions in the field of biochemistry and drug discovery.
Leadership and Management Experience
Mark Witmer has over 14 years of experience as a group leader of the protein science group at Bristol-Myers Squibb. He co-leads a cross-functional biophysics and ligand binding community of practice within the BMS Discovery organization. Additionally, he has more than 12 years of experience in managing and leading outsourcing protein production and biophysical projects with multiple CROs. He is also an experienced mentor and manager of scientific teams.
Commitment to Patient Safety and Public Health
Mark Witmer has a strong commitment to patient safety and public health. He administers three legacy Celgene REMS programs that include Elements to Assure Safe Use (ETASU). Working closely with patients' physicians, he determines the best course of action for pre-approval access to investigational medicines, ensuring they are provided in a fair and equitable manner. His efforts support global treatment access and the development of bioequivalent, small molecule generic drugs approved by regulatory authorities.